Prosecution Insights
Last updated: November 20, 2026
Application No. 18/371,656

METHOD AND SYSTEM FOR PREDICTING ADHERENCE TO A TREATMENT

Non-Final OA §101§DOUBLEPATENT
Filed
Sep 22, 2023
Priority
Feb 09, 2009 — provisional 61/151,152 +2 more
Examiner
LE, LINH GIANG
Art Unit
3686
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Fair Isaac Corporation
OA Round
4 (Non-Final)
66%
Grant Probability
Favorable
4-5
OA Rounds
4m
Est. Remaining
62%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
462 granted / 695 resolved
+14.5% vs TC avg
Minimal -5% lift
Without
With
+-4.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
10 currently pending
Career history
717
Total Applications
across all art units

Statute-Specific Performance

§101
33.2%
-6.8% vs TC avg
§103
32.3%
-7.7% vs TC avg
§102
12.4%
-27.6% vs TC avg
§112
13.6%
-26.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 695 resolved cases

Office Action

§101 §DOUBLEPATENT
DETAILED ACTION Notice to Applicant This communication is in response to Amendment and Remarks dated 5/11/26. Claims 1, 9-11, 14, and 18-20 have been amended. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 11,804,306 and claims 1-12 of U.S. Patent No.10,853,900. Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims of the previously patented claims anticipate and/or are an obvious variant of the currently pending claims. The previously patented claims are an obvious variant of the currently pending claims. The currently amended independent claims require substantially the same adherence modeling, scoring, timeline messaging, and population-based treatment administration as the claims of the ‘306 and ‘900 patents. The principal differences are: 1. expressly identifying divergence-based optimization as the model-training technique; 2. expressly updating the score following receipt of later subject data; and 3. characterizing the selected regimen as tailored to a specific population rather than generic. These differences do not establish patentable distinctness. First, the issued claims already require training a predictive model using population-derived adherence data. Selecting divergence-based optimization merely specifies a mathematical objective for performing that existing training function and yields the expected result of fitting the model to adherence data. Second, ’900 claim 4 expressly recalculates continued adherence likelihood using data received after treatment begins. Because the score in ’900 claim 1 is based on the model-generated adherence likelihood, updating that score after recalculating the likelihood would have been a predictable use of the patented scoring process. Third, the issued claims already compare the individual patient’s characteristics with characteristics of a previously treated population and administer treatment based on the resulting scores and segmentation. Expressly describing that treatment as population-tailored states the expected result of the patented population-based treatment framework. Accordingly, the pending independent claims recite obvious variants of the inventions defined by the issued claims rather than a patentably distinct invention. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-5, 9-15, and 18-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Claims 1-10 are drawn to a system for predicting adherence to a treatment, which is within the four statutory categories (i.e. machine). Claims 11-17 are drawn to a computer program product for predicting adherence to a treatment, which is within the four statutory categories (i.e. article of manufacture). Claims 18-20 are drawn to a method for predicting adherence to a treatment, which is within the four statutory categories (i.e. process). Representative independent claim 1 includes limitations that recite at least one abstract idea. Specifically, independent claim 1 recites: A treatment administration system comprising at least one programmable processor executing logic code causing the treatment administration system to perform operations comprising: extracting a combined set of variables from first data collected from treatment adherence patterns associated with one or more treatments administered to a plurality of treatment subjects including a first treatment subject characterized by second data; determining a likelihood of adherence to a first treatment regimen for the first treatment subject, based on the combined set of variables populating a computer- implemented model wherein divergence-based optimization is applied to the computer-implemented model, using the treatment adherence patterns, to train the computer-implemented model with respect to the likelihood of a population of treatment subjects adhering to the first treatment regimen, the likelihood of adherence determined in response to computing one or more values for the combined set of variables by using data associated with at least one treatment subject at a plurality of stages of the first treatment regimen, transmitting one or more messages according to a timeline to a computing device to provide optimized treatment to the first treatment subject in accordance with the one or more messages, the timeline generated based on data characterizing the determined likelihood of adherence, and wherein the first treatment regimen is administered to the first treatment subject according to a metric including a first score generated for the first treatment subject wherein the first score is updated responsive to at least one variable associated with the second data affecting the likelihood of the first treatment subject adhering to the first treatment regimen, and the first treatment regimen being a specific treatment regimen selected for administration to a specific population of treatment subjects to which the first treatment subject belongs, wherein the specific treatment regimen is tailored to the specific population rather than a generic treatment regimen. The limitations directed to determining whether a treatment subject is likely to follow a treatment regimen, assigning or updating an adherence score, and transmitting timed messages to encourage or guide compliance recite managing personal behavior and interactions involving instructions or guidance. Under the broadest reasonable interpretation, the claimed process evaluates a person’s anticipated compliance with prescribed conduct and uses the evaluation to determine when communications should be provided to influence that conduct. This falls within the “managing personal behavior or relationships or interactions between people” subgrouping of certain methods of organizing human activity (managing personal behavior or relationships or interactions between people (including social activities, teaching, and following rules or instructions -- see MPEP § 2106.04(a)(2), subsection II). That is other than reciting “a computer-implemented model”; and “computing device” language, nothing in the claim element precludes the steps from practically being performed between people or by a person. If a claim limitation, under its broadest reasonable interpretation, covers interactions between people or managing personal behavior or relationships then it falls within the “Certain Methods of Organizing Human Activity” grouping of abstract ideas. Accordingly, the claim recites an abstract idea. Claim 1 additionally recites: computing values for a combined set of variables; determining a likelihood; generating and updating a score; and applying divergence-based optimization to a model. These limitations recite mathematical calculations and mathematical optimization. “Divergence-based optimization” identifies a mathematical technique or class of techniques used to train the model and generate adherence-related output. The mathematical analysis is used to perform the adherence-evaluation and behavior-management process. Accordingly, claim 1 recites both mathematical concepts and a certain method of organizing human activity. In the present case, the additional limitations beyond the above-noted at least one abstract idea are as follows (where the bolded portions are the “additional limitations” while the underlined portions continue to represent the at least one “abstract idea”): A treatment administration system comprising at least one programmable processor executing logic code causing the treatment administration system to perform operations comprising: extracting a combined set of variables from first data collected from treatment adherence patterns associated with one or more treatments administered to a plurality of treatment subjects including a first treatment subject characterized by second data; determining a likelihood of adherence to a first treatment regimen for the first treatment subject, based on the combined set of variables populating a computer- implemented model wherein divergence-based optimization is applied to the computer-implemented model, using the treatment adherence patterns, to train the computer-implemented model with respect to the likelihood of a population of treatment subjects adhering to the first treatment regimen, the likelihood of adherence determined in response to computing one or more values for the combined set of variables by using data associated with at least one treatment subject at a plurality of stages of the first treatment regimen, transmitting one or more messages according to a timeline to a computing device to provide optimized treatment to the first treatment subject in accordance with the one or more messages, the timeline generated based on data characterizing the determined likelihood of adherence, and wherein the first treatment regimen is administered to the first treatment subject according to a metric including a first score generated for the first treatment subject, wherein the first score is updated responsive to at least one variable associated with the second data affecting the likelihood of the first treatment subject adhering to the first treatment regimen, and the first treatment regimen being a specific treatment regimen selected for administration to a specific population of treatment subjects to which the first treatment subject belongs, wherein the specific treatment regimen is tailored to the specific population rather than a generic treatment regimen. For the following reasons, the Examiner submits that the above identified additional limitations do not integrate the above-noted at least one abstract idea into a practical application. The additional elements (i.e. the limitations not identified as part of the abstract idea) amount to no more than limitations which: amount to mere instructions to apply an exception, see MPEP 2106.05(f). the recitations performing the functions by the computer amounts to merely invoking a computer as a tool to perform the abstract idea, e.g. see paragraph [0027] of the present Specification. The recitation of wherein the first treatment regimen is administered to the first treatment subject according to a metric including a first score generated for the first treatment subject… and the first treatment regimen being a specific treatment regimen selected for administration to a specific population of treatment subjects to which the first treatment subject belongs, wherein the specific treatment regimen is tailored to the specific population rather than a generic treatment regimen. recites only the idea of a solution or outcome (i.e. claim fails to recite details of how a solution to a problem is accomplished). The claim teaches generally administering a “first treatment regimen” according to a first score. This does not amount to a particular treatment and merely teaches instructions to apply an exception. See MPEP 2106.04 (d)(2). Characterizing an unidentified regimen as “specific,” “tailored,” or “rather than generic” does not define the treatment itself. Under the broadest reasonable interpretation, the limitation encompasses administering any unspecified regimen selected for any group identified through the adherence analysis. The recitation of wherein the first score is updated responsive to at least one variable associated with the second data affecting the likelihood of the first treatment subject adhering to the first treatment regimen recites only the idea of a solution or outcome (i.e. claim fails to recite details of how a solution to a problem is accomplished). Updating the score responsive to a variable affecting adherence likelihood further refines the abstract analytical process. It remains an act of receiving information, mathematically reassessing adherence likelihood, and updating the resulting score. The claim does not require that the score update cause a defined technical change in a medical device or treatment-delivery mechanism. Accordingly, the score-update limitation does not meaningfully limit the judicial exception. generally link the abstract idea to a particular technological environment or field of use, see MPEP 2106.05(h)– for example, the recitation merely limits the abstract idea to the field of medicine and transmitting messages to a computing device merely limits the abstract ideas to computers. Furthermore, the limitations of a computer-implemented model and at least one programmable processor executing logic code generally link the recited abstract idea to a computer environment. Thus, taken alone, the additional elements do not integrate the at least one abstract idea into a practical application. Independent claim 1 does not include additional elements that are sufficient to amount to “significantly more” than the judicial exception. As discussed above with respect to discussion of integration of the abstract idea into a practical application, the additional elements amount to no more than mere instructions to apply an exception and generally linking the abstract idea to a particular technological environment or field of use and the same analysis applies with regards to whether they amount to “significantly more.” Therefore, the additional elements do not add significantly more to the at least one abstract idea. As per claim 11, the claim teaches limitations similar to claim 1 and the same abstract idea (“mental processes”) for the same reasons as stated above. Claim 11 further teaches a computer program product to perform the functionality taught by claim 1. These limitations of a non-transitory machine-readable medium and processor as generally recited, amount to mere instructions to apply an exception, see MPEP 2106.05(f) and generally link the abstract idea to a particular technological environment or field of use, see MPEP 2106.05(h). Independent claim 11 is directed to an abstract idea. As per claim 18, the claim teaches limitations similar to claim 1 and the same abstract idea (“mental processes”) for the same reasons as stated above. Claim 18 further teaches a computer-implemented model to perform the functionality taught by claim 1. These limitations of a learning and predictive component and computer processors, as generally recited, amount to mere instructions to apply an exception, see MPEP 2106.05(f) and generally link the abstract idea to a particular technological environment or field of use, see MPEP 2106.05(h). Independent claim 18 is directed to an abstract idea. Furthermore, for similar reasons as representative independent claim 1, analogous independent claims 11 and 18 do not recite additional elements that integrate the judicial exception into a practical application nor add significantly more. Claims 2, 4–5, 9–10, 12, 14–15, and 19–20 further define the scoring, monitoring, messaging, updating, and treatment-administration process but do not cure the deficiencies of the independent claims. Claims 2, 12, and 20 extend the same abstract adherence-scoring and regimen-selection process to another subject. Claims 4, 14, and 20 assign subjects to disjoint score ranges and use a score as a monitoring metric. These limitations further refine the abstract classification and evaluation process. Claims 5 and 15 deliver messages based on the score ranges and therefore further recite behavior-management communications. Claims 9 and 19 receive later subject data and update the score, further refining the abstract data-analysis process. Claims 10 and 19 administer an updated regimen based on the updated score and combine variables based on interdependence. The regimen remains unidentified, while the interdependence limitation further recites mathematical or analytical evaluation. The dependent claims further do not include additional elements (considered both individually and as an ordered combination) that are sufficient to amount to significantly more than the judicial exception for the same reasons to those discussed above with respect to determining that the dependent claims do not integrate the at least one abstract idea into a practical application. Therefore, claims 1-5, 9-15, and 18-20 are ineligible under 35 USC §101. Subject Matter free from Prior Art Claims 1-20 teach subject matter free from prior art. Weickert (2008/0228525), teaches a system that is able to generate a report including a diagnosis of an individual’s health and adherence of an individual to a treatment prescribed by a physician in the past. The physician can modify a treatment based on this report. (see paras. [0047] — [0067], Tables 1-5). Glauser (8,589,175) teaches identifying scientific data about efficacy and tolerability of therapeutic modalities (treatments). (see paras. [00135] — [00148)). Brown (WO-0137174-A1) teaches a method and system and computer program product for remotely measuring one's adherence to a diet program. Ozminokowski (Ozminkowski, Ronald J; White, Alan J; Hassol, Andrea; Murphy, Michael. “General health of end stage renal disease program beneficiaries.” Health Care Financing Review 19.n1: p121 (24). Superintendent of Documents. (Oct 1997 -Dec 1997)) teaches expanding methods used to assess health status among ESRD patients and obtaining health information and health status and its determinants. Shargie (Shargie, Estifanos Biru; Lindtjorn, Bernt. “Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia.” Pl o S Medicine 4.2: 280(8). Public Library of Science. (Feb 2007)) teaches determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. The closest prior art of record teaches comparing and analyzing treatment data but fails to expressly teach: extracting a combined set of variables from first data collected from treatment adherence patterns associated with one or more treatments administered to the a plurality of treatment subjects including a first treatment subject characterized by second data; determining a likelihood of adherence to a first treatment regimen for the first treatment subject, based on the combined set of variables populating the a computer-implemented model, wherein divergence-based optimization is applied to the computer-implemented model, using the treatment adherence patterns, to train the computer-implemented model with respect to the likelihood of a population of treatment subjects adhering to the first treatment regimen; the likelihood of adherence determined in response to computing one or more values for the combined set of variables by using data associated with at least one treatment subject at a plurality of stages of the first treatment regimen, transmitting one or more messages according to a timeline to a computing device to provide optimized treatment to the first treatment subject in accordance with the one or more messages, the timeline generated based on data characterizing the determined likelihood of adherence, and wherein the first treatment regimen is administered to the first treatment subject according to a metric including a first score generated for the first treatment subject based on the determined likelihood of adherence of the first treatment subject, wherein the first score is updated responsive to at least one variable associated with the second data affecting the likelihood of the first treatment subject adhering to the first treatment regimen, and the first treatment regimen being a specific treatment regimen selected for administration to a specific population of treatment subjects to which the first treatment subject belongs, wherein the specific treatment regimen is tailored to the specific population rather than a generic treatment regimen. No final decision on patentability has been made in light of pending rejections. Response to Arguments Applicant's arguments filed 7/29/2026 have been fully considered but they are not persuasive. Applicant argues on pg. 11 of the 5/11/26 Remarks that the claims improve treatment administration by generating an adherence score, an optimized timeline, and population-tailored treatment. This argument is not persuasive because the claims principally recite collecting and analyzing adherence information, generating a likelihood and score, and transmitting messages intended to encourage adherence. The asserted improvements in treatment effectiveness, segmentation, agility, and patient outcomes are desired results rather than specific improvements to computer functionality or another technological process. The claims do not recite an improvement to the operation of the processor, model architecture, memory, network, or communication system. Nor do they recite how the alleged reduction in computational processing is achieved. Merely using a computer-generated score in a medical-treatment environment does not, by itself, integrate the abstract analysis into a practical application. Next on pg. 11 of the Remarks, Applicant’s reliance on claim 2 of Example 49 is not persuasive. Example 49 does not hold that any treatment characterized as “specific” or “population-tailored” is sufficient. The eligible claim affirmatively required administering an identified treatment—Compound X eye drops—to the identified patient population. The USPTO’s guidance requires that the treatment be sufficiently particular and specifically identified. Instead, the claims characterize an otherwise unspecified regimen as “specific” because it is selected for a population and is “tailored” rather than generic. That language does not meaningfully define the treatment itself and encompasses substantially any treatment selected using the model’s output. Accordingly, the pending claims are more analogous to analytical claims that generate and communicate information than to Example 49’s affirmative administration of an identified treatment. Examiner agrees with Applicant’s assertion on pg. 12 that Example 49 does not require both a particular dosage and frequency. However, this does not establish that an entirely unidentified treatment is sufficient. The relevant distinction is between – 1) an identified treatment that need not additionally specify its dosage or frequency; and 2) a generic reference to administering some “specific” or “tailored” regimen without identifying what the regimen is. The pending claims fall within the second category. Thus, Applicant’s argument incorrectly treats the absence of a dosage requirement as eliminating the separate requirement that the treatment itself be sufficiently particular. Next on pg. 14, Applicant relies on Vanda and argue that the pending claims are similar to those found eligible in Vanda. However, the cited treatment decisions are distinguishable. Vanda involved administration of a specifically identified drug within a claimed dosage range based on the patient’s metabolic status. The claims therefore applied the diagnostic relationship through a concrete therapeutic action. The pending claims do not identify a drug, dosage, treatment modality, or other therapeutic parameter. Instead, they generate an adherence prediction and communicate messages concerning an unspecified regimen. The mere presence of the word “administered” does not make a claim equivalent to the specific treatment claims in Vanda. Further, Applicant’s analogy to Example 40 on pg 15 of the Remarks is not persuasive. Example 40 recited a specific change in computer operation: network usage information was collected only when a calculated condition was satisfied, thereby avoiding continuous collection and reducing network and processing demands. The eligibility determination was based on claim language that actually required the selective data-collection operation. The pending independent claims do not require: selectively collecting data only when the score satisfies a condition; reducing the frequency or quantity of data collection; deleting or compressing underlying variables; reducing processor, memory, bandwidth, or network usage; or monitoring using only the score instead of the underlying variables. Applicant relies on specification statements concerning operational efficiency, but the claimed score is still generated from and updated using the underlying variables. Nothing in the claims requires reduced computational processing. An asserted benefit in the specification cannot substitute for a claimed technological mechanism that produces that benefit. Claim 4 likewise recites the result of “enabling efficient treatment administration,” but does not specify operations that reduce resource consumption. The phrase “using a single metric for each treatment subject” does not establish that the computer avoids processing the underlying data or operates differently from conventional systems. Next on pg. 17 of the Remarks, Applicant traverses the pending rejection under 35 USC 101. Specifically, Applicant’s argument that the claims are not directed to “certain methods of organizing human activity” are not persuasive. The claims evaluate a subject’s likelihood of following a treatment regimen and transmit sequential messages intended to increase adherence. Treatment adherence concerns whether an individual follows prescribed conduct, and communicating reminders or guidance based on predicted compliance falls within managing personal behavior and interactions involving instructions or guidance. The use of a predictive model and mathematical optimization does not remove the claimed activity from the abstract-idea grouping. It implements the adherence-management process using mathematical analysis and generic computing operations. Furthermore, Examiner disagrees with Applicant’s reliance to Ancora Technologies on pg. 19 of the Remarks. Ancora is distinguishable because those cases involved specifically claimed improvements to computer functionality. The pending claims do not identify a technological defect in prior computers or recite a new data structure, memory arrangement, security technique, or model architecture that improves the computer itself. The alleged improvement concerns treatment-adherence management, not computer operation. Applicant next tries to argue that the claims teach a practical application under Step 2A, Prong 2. The additional elements do not integrate the abstract idea into a practical application. The processor, computer-implemented model, computing device, and message transmission perform generic computer functions. The treatment clause does not identify or control a particular treatment, and the timeline is used to transmit information. Considered individually and in combination, the additional elements amount to using generic computing components to analyze adherence data and communicate the analytical result. Applicant’s reliance on BASCOM on pg. 22 is not persuasive. BASCOM involved a specific and allegedly unconventional placement and arrangement of filtering functionality within a network. The pending claims do not recite a comparable technical architecture. They recite functional objectives—extracting variables, predicting adherence, generating a score, transmitting messages, and administering an unspecified regimen—without specifying a nonconventional computer arrangement. Applicant’s assertion that prior systems did not combine the claimed functions is a conclusory statement. Moreover, the claimed arrangement must provide an inventive concept beyond the abstract idea itself. Predictive modeling, score generation, and timed communications are integral parts of the adherence-management concept and cannot supply “significantly more” merely because they are recited together. Finally, Applicant’s lack-of-preemption argument on pgs. 23-24 is not dispositive. A claim may fail the eligibility analysis even though it does not preempt every application of the abstract idea. McRO involved specific claimed rules that constrained automated animation to a particular technological process. The pending claims do not recite comparably specific rules governing computer operation. “Divergence-based optimization” identifies a general class of mathematical techniques without claiming a particular divergence measure, objective function, constraints, or computational implementation. Accordingly, the claims’ failure to cover all adherence-management systems does not establish eligibility. On pg. 24 of the Remarks Applicant traverses the currently Double Patenting rejection. The rejection has been updated in light of Applicant’s amendments and the arguments are now moot. It is noted that Examiner has made a proper updated Double Patenting rejection in light of the amendments and has clearly established how the pending claims are obvious in view of the issued patents. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LINH GIANG MICHELLE LE whose telephone number is (571)272-8207. The examiner can normally be reached Mon- Fri 8:30am - 5:30pm PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JASON DUNHAM can be reached at 571-272-8109. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LINH GIANG "MICHELLE" LE PRIMARY EXAMINER Art Unit 3686 /LINH GIANG LE/Primary Examiner, Art Unit 3686 7/29/26
Read full office action

Prosecution Timeline

Show 4 earlier events
Nov 24, 2025
Response after Non-Final Action
Dec 23, 2025
Request for Continued Examination
Jan 29, 2026
Response after Non-Final Action
Feb 11, 2026
Non-Final Rejection mailed — §101, §DOUBLEPATENT
Mar 11, 2026
Examiner Interview Summary
May 11, 2026
Response Filed
Aug 03, 2026
Final Rejection mailed — §101, §DOUBLEPATENT
Oct 05, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12802814
INTELLIGENT JOINT PROSTHESIS
1y 7m to grant Granted Nov 17, 2026
Patent 12751801
Validation for the Placement and Generation of Components for Dental Restoration Appliances
1y 9m to grant Granted Oct 06, 2026
Patent 12744119
Capital Equipment Auto-Enabled Features
3y 1m to grant Granted Sep 22, 2026
Patent 12744127
PREDICTING ANALYTE LEVELS BASED ON INTERMITTENT SENSOR DATA
2y 1m to grant Granted Sep 22, 2026
Patent 12738371
SYSTEMS AND METHODS FOR RETRIEVING PART SERVICE HISTORY DURING SERVICING OF A MEDICAL DEVICE
2y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
66%
Grant Probability
62%
With Interview (-4.7%)
3y 6m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 695 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month